Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hesketh

Showing results (181-190 of 248) with videos related to

Pageof 25
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 11, 2008
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamidePaul J Hesketh, Jerry Younger, Pedro Sanz-Altamira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Proposal for classifying the acute emetogenicity of cancer chemotherapyP J Hesketh, M G Kris, S M Grunberg, et al.
Journal of the American College of Radiology : JACR|February 6, 2016
Experience With a CT Screening Program for Individuals at High Risk for Developing Lung CancerBrady J McKee, Jeffrey A Hashim, Robert J French, et al.
Journal of the American College of Radiology : JACR|September 2, 2014
Experience with a CT screening program for individuals at high risk for developing lung cancerBrady J McKee, Jeffrey A Hashim, Robert J French, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2007
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119Wallace Akerley, Jason McCoy, Paul J Hesketh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 2, 2006
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment responseP J Hesketh, S M Grunberg, J Herrstedt, et al.
Biochimica Et Biophysica Acta. Biomembranes|January 17, 2020
Styrene maleic-acid lipid particles (SMALPs) into detergent or amphipols: An exchange protocol for membrane protein characterisationSophie J Hesketh, David P Klebl, Anna J Higgins, et al.
Plos One|December 29, 2015
The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of ExtravasationAnthony J Hesketh, Caroline Maloney, Christopher A Behr, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsP J Hesketh, S Van Belle, M Aapro, et al.
Journal of Geriatric Oncology|November 28, 2016
Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patientsMatti Aapro, Karin Jordan, Richard J Gralla, et al.
Pageof 25

Showing results (181-190 of 248) with videos related to

Sort By:
Pageof 25
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 11, 2008
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamidePaul J Hesketh, Jerry Younger, Pedro Sanz-Altamira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Proposal for classifying the acute emetogenicity of cancer chemotherapyP J Hesketh, M G Kris, S M Grunberg, et al.
Journal of the American College of Radiology : JACR|February 6, 2016
Experience With a CT Screening Program for Individuals at High Risk for Developing Lung CancerBrady J McKee, Jeffrey A Hashim, Robert J French, et al.
Journal of the American College of Radiology : JACR|September 2, 2014
Experience with a CT screening program for individuals at high risk for developing lung cancerBrady J McKee, Jeffrey A Hashim, Robert J French, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2007
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119Wallace Akerley, Jason McCoy, Paul J Hesketh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 2, 2006
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment responseP J Hesketh, S M Grunberg, J Herrstedt, et al.
Biochimica Et Biophysica Acta. Biomembranes|January 17, 2020
Styrene maleic-acid lipid particles (SMALPs) into detergent or amphipols: An exchange protocol for membrane protein characterisationSophie J Hesketh, David P Klebl, Anna J Higgins, et al.
Plos One|December 29, 2015
The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of ExtravasationAnthony J Hesketh, Caroline Maloney, Christopher A Behr, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsP J Hesketh, S Van Belle, M Aapro, et al.
Journal of Geriatric Oncology|November 28, 2016
Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patientsMatti Aapro, Karin Jordan, Richard J Gralla, et al.
Pageof 25